PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

  1. 729 Posts.
    lightbulb Created with Sketch. 138
    imo $6.3m is quite a disappointing R&D rebate estimate.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.